Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 411-418

  Lotz, Jean Pierre ^a   Bui, B ^b   Gomez, F ^c   Theodore C ^d   Caty, A ^e   Fizazi, K ^d   Gravis, G ^f   Delva, R ^g   Peny, J ^h   Viens, P ^f   Duclos, B ⁱ   De Revel, T ^j   Cure H ^k   Gligorov, J ^a   Guillemaut, S ^c   Segura C ^c   Provent, S ^a   Droz, J P ^c   Culine, S ^l   Biron, P ^c  

^a HÔPITAL TENON   (France)

^b INSTITUT BERGONIÉ   (France)

^c CENTRE LÉON BÉRARD   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e CENTRE OSCAR LAMBRET   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g CENTRE PAUL PAPIN   (France)

^h CENTRE FRANÇOIS BACLESSE   (France)

ⁱ CENTRE PAUL STRAUSS   (France)

^j PERCY MILITARY HOSPITAL   (France)

^k CENTRE JEAN PERRIN   (France)

^l CENTRE VAL D AURELLE   (France)

more..

Author keywords

Germ cell tumors; High dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; THIOTEPA;

ACUTE RESPIRATORY TRACT DISEASE; ADOLESCENT; ADULT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RELAPSE; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG MEGADOSE; DRUG RESPONSE; FEVER; FOLLOW UP; GERM CELL TUMOR; HEMORRHAGIC CYSTITIS; HUMAN; LIVER TOXICITY; MALE; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SALVAGE THERAPY; SCORING SYSTEM; STEM CELL MOBILIZATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TOXIC SHOCK SYNDROME; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING;

EID: 20144388986     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi087     Document Type: Article

References (52)

1. Einhorn LH. Curing metastatic testicular cancer. Proc Natl Acad Sci USA 2002; 99: 4592-4595.
2. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
3. Benedetto P. Chemotherapy of testis cancer. Cancer Control 1999; 6: 549-559.
4. International Germ Cell Cancer Consensus Classification. A prognostic factor-based staging for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15: 595-603.
5. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol 1997; 15: 2559-2563.
6. Loehrer PJ, Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 1998; 16: 2500-2504.
7. Hartmann JT, Nichols CR, Droz JP et al. Prognostic variables for response and outcome in patients with extra-gonadal germ-cell tumors. Ann Oncol 2002; 13: 1017-1028.
8. Postmus PE, de Vries EG, de Vries-Hospars HG et al. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation: a dose escalation study. Eur J Cancer Clin Oncol 1984; 20: 777-782.
9. Nichols CR, Williams SD, Loehrer PJ et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a South-Eastern Cancer Study Group and Southwest Oncology Group Protocol. J Clin Oncol 1991; 9: 1163-1172.
10. Nichols CR, Tricot G, Williams SD et al. Dose intensive chemotherapy in refractory germ cell cancer: a phase I-II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932-939.
11. Motzer RJ, Mazumdar M, Gulati SC et al. Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 1993; 85: 1828-1835.
12. Broun ER, Nichols CR, Tricot G et al. High-dose carboplatin/VP-16 and ifosfamide with autologous bone marrow support in the treatment of refractory germ cell tumors. Bone Marrow Transplant 1991; 7: 53-56.
13. Lotz JP, André T, Donsimoni R et al. High dose chemotherapy with ifosfamide, carboplatin and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adult. Cancer 1995; 75: 874-885.
14. Bhatia S, Abonour R, Porcu P et al. High dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol 2000; 18: 3346-3351.
15. Rodenhuis S, De Wit R, De Mulder PH et al. A multi-centre prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol 1999; 10: 1467-1473.
16. Brown ER, Nichols CR, Kneebone P et al. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124-128.
17. Siegert W, Beyer J. Germ cell tumors: dose-intensive therapy. Semin Oncol 1998; 25: 215-223.
18. Beyer J, Stenning S, Gerl A et al. High-dose versus conventional-dose first-salvage treatment in non-seminoma: a matched-pair analysis. Proc Am Soc Clin Oncol 1999; 19: 326a (Abstr 1255).
19. Linkesch W, Greinix HT, Hocker P. Long-term follow-up of phase I-II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapse non seminomatous germ cell tumors. Proc Am Soc Clin Oncol 1993; 12: 232 (Abstr 717).
20. Beyer J, Kramar A, Mandanas R et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol 1996; 14: 2638-2645.
21. Lecesne A, Droz JP, Azab M et al. Phase II trial with single agent epirubicin as salvage chemotherapy in refractory germ cell tumors. Proc Am Soc Clin Oncol 1990; 9: 145 (Abstr 563).
22. Madani AA, George DW, Brames JM et al. Phase II study of epirubicin plus cisplatin in refractory germ cell tumors. Proc Am Soc Clin Oncol 2003; 22: 388 (Abstr 1557).
23. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II of trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994; 12: 2277-2283.
24. Bokemeyer C, Beyer J, Metzner B et al. Phase II study of paclitaxel in patients with relapsed or cisplatin refractory testicular cancer. Ann Oncol 1996; 7: 31-34.
25. De Wit R, Louwerens M, de Mulder PH et al. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 1999; 83: 831-833.
26. Bengala C, Giannessi PG, Baldini E et al. Epirubicin (EpiADM), paclitaxel (TXL) and G/GM-CSF can mobilize peripheral blood progenitor cells (PBPCs) to support a myelosuppressive treatment in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1996; 15: 348 (Abstr 1017).
27. Veldhuis JG, Willemse PHB, Beijren JH et al. Paclitaxel, ifosfamide and cisplatin with G-CSF or recombinant human interleukin 3 and G-CSF in ovarian cancer: a feasibility study. Br J Cancer 1997; 75: 703-709.
28. Rodenhuis S, Van der Wall E, Schornage JH et al. Development of a multiple high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa and carboplatin with peripheral stem-cell transplantation. Proc Am Soc Clin Oncol 1994; 13: 248 (Abstr).
29. Lotz JP, Bui B, Théodore C et al. Refractory germ cell tumors (GCTs): salvage high-dose chemotherapy (HD-CT) combining 2 mobilization regimens followed by 3 HD-CT with peripheral blood stem cell transplantation (PBSCT): the TAXIF regime (GETUG). Proc Am Soc Clin Oncol 2002; 21: 187a (Abstr).
30. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961; 13: 346-353.
31. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology group. Am J Clin Oncol 1982; 5: 649-655.
32. Miller AB, Hoogstraten B, Staquet M, Winckler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
33. Kaplan ER, Meier P. Non-parametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-489.
34. Merad-Boudia Z, Lotz JP, Aloulou S et al. Extra-haematological toxicity-related deaths in the treatment of solid tumors with high-dose chemotherapy and autologous stem cell transplantation: a retrospective study in a single institution. Proc Am Soc Clin Oncol 2000; 19: 61a (Abstr 237).
35. Rick O, Kollmannsberger C, Hartmann JT et al. The role of high-dose chemotherapy in relapsed germ cell tumors. World J Surg 2004; 22: 25-32.
36. Vaena DA, Abonour R, Einhorn LH. Long-term survival after highdose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol 2003; 21: 4100-4104.
37. Horwich A. Salvage therapy of germ cell tumors. Br J Cancer 1995; 71: 901-903.
38. De Giorgi U, Papiani G, Severini G et al. High dose chemotherapy in adult patients with germ cell tumors. Cancer Control 2003; 10: 48-56.
39. Droz JP, Kramar A, Pico JL. Prediction of long-term response after high dose chemotherapy with ABMT in the salvage treatment of non-seminomatous germ cell tumors. Eur J Cancer 1993; 29A: 818-821.
40. Motzer RJ, Mazumdar M, Bosl GJ et al. High dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol 1996; 14: 1098-1105.
41. Rodenhuis S, Westermann A, Holtkamps MJ et al. Feasibility of multiple courses of high dose cyclophosphamide, thiotepa and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996; 14: 1473-1483.
42. Rosti G, Pico JL, Wandt H et al. High dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ-cell tumors: first results of a prospective randomized trial of the European Group for Bone and Blood Transplantation (EBMT). The IT-94 study. Proc Am Soc Clin Oncol 2002; 21: 180a (Abstr 716).
43. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J Clin Oncol 2000; 18: 1173-1180.
44. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000; 18: 2413-2418.
45. Shamash J, O'Doherty CA, Oliver RT et al. Should high dose chemotherapy be used to consolidate second or third line treatment in refractory germ cell tumours? Acta Oncol 2000; 39: 857-863.
46. Rick O, Bokemeyer C, Beyer J et al. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer. J Clin Oncol 2001; 19: 81-88.
47. McNeish IA, Kanfer EJ, Haynes R et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer 2004; 90: 1169-1175.
48. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose chemotherapy. J Clin Oncol 1992; 10: 102-110.
49. Schmoll HJ, Kollmannsberger C, Metzner B et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group. J Clin Oncol 2003; 21: 4083-4091.
50. Hartmann JT, Schleuler N, Metzner B et al. Sequential HD VIP-chemotherapy with autologous PBSC-transplantation as first-line treatment in patients with primary mediastinal non-seminomatous germ cell cancer. Proc Am Soc Clin Oncol 2002; 21: 186a (Abstr 741).
51. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399.
52. Fields KF, Perkins JB, Partyka JS et al. High-dose thiotepa, novantrone, and taxol (TNT) followed by autologous stem cell transplant; results of a phase II study in women with chemoresponsive metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 49a (Abstr 182).